New hope for pouchitis sufferers: experimental drug enters trial
NCT ID NCT07226050
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests an experimental drug called CLF065 in 20 adults with chronic pouchitis, a condition causing inflammation in a surgically created internal pouch. Participants receive weekly doses of CLF065 or a placebo to see if the drug safely reduces symptoms and inflammation. The goal is to find a better treatment option for this long-term condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POUCHITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lenox Hill Hospital
New York, New York, 10075, United States
-
Phillip Fleshner, M.D. Inc
Los Angeles, California, 90048, United States
-
Scripps Health
La Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a stool transplant calm an inflamed pouch?
- Can a common antibiotic stop pouchitis from coming back?
- New combo tackles stubborn gut inflammation after colitis surgery
- Stem cell shot for pouchitis fails to launch
- New drug aims to stop pouchitis before it starts